Evoke Pharma Inc

Overview

• IndustryPharmaceutical Preparations²
• HeadquartersSolana Beach, United States²
• Incorporated inDE³
• Business address420 Stevens Avenue, Suite 230, Solana Beach, Ca 92075³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI529900Q01Z5E3L6MZZ66²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4292392²

See how the biggest companies compare on our leaderboards

We are a specialty pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal (“GI”) disorders and diseases. Since our inception, we have devoted our efforts to developing our sole product, Gimoti ® (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. In June 2020, we received approval from the United States Food and Drug Administration (“FDA”) for our 505(b)(2) New Drug Application for Gimoti (the “Gimoti NDA”). We launched commercial sales of Gimoti in the United States in October 2020 through our commercial partner, Eversana Life Science Services, LLC (“Eversana”).⁴ From its latest annual report

Corporate structure

Evoke Pharma Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Evoke Pharma Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Inventory

Properties, in its own words

We occupy approximately 1,500 square feet of office space in Solana Beach, California under a lease that we entered into in October 2024. We believe that our facility is adequate to meet our needs and that, if necessary, additional space can be leased to accommodate any future growth on commercially reasonable terms.

Item 2 of the 10-K filed Mar 13, 2025.⁴

Leadership

Who has led Evoke Pharma Inc, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMatthew J. D'Onofrio Aug 8, 2024 to now¹⁵
• Chief executive officerDavid A. Gonyer Sep 24, 2013 to Feb 10, 2023¹⁶
• PresidentMatthew J. D'Onofrio Feb 10, 2023 to Feb 10, 2023¹⁷
• PresidentDavid A. Gonyer Sep 24, 2013 to Feb 4, 2022¹⁶
• Chief financial officerMark Kowieski May 30, 2024 to now¹⁸

Timeline

1. Dec 17, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights³⁰
2. Nov 13, 20258-K Results of operations³¹
3. Nov 4, 20258-K Entered a material agreement; Executive or director change; Other events³²
4. Aug 14, 20258-K Results of operations³³
5. Aug 6, 20258-K Other events³⁴
6. Jul 9, 20258-K Other events³⁵
7. May 22, 20258-K Shareholder vote³⁶
8. May 13, 20258-K Results of operations³⁷
9. Mar 13, 20258-K Results of operations³⁸
10. Feb 24, 20258-K Executive or director change³⁹
11. Nov 7, 20248-K Results of operations⁴⁰
12. Oct 28, 20248-K Other events⁴¹
13. Aug 8, 2024New chief executive Matthew J. D'Onofrio becomes CEO¹⁵
14. Sep 24, 2013New chief executive David A. Gonyer becomes CEO¹⁶

Calendar

When it reported results

1. Nov 13, 2025Reported quarterly or annual results³¹
2. Aug 14, 2025Reported quarterly or annual results³³
3. May 13, 2025Reported quarterly or annual results³⁷
4. Mar 13, 2025Reported quarterly or annual results³⁸
5. Nov 7, 2024Reported quarterly or annual results⁴⁰
6. Aug 13, 2024Reported quarterly or annual results⁴²
7. May 14, 2024Reported quarterly or annual results⁴³
8. Mar 14, 2024Reported quarterly or annual results⁴⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

247 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 69 major events, 62 insider forms, 19 large holders, 79 other. The latest 20:

1. Dec 30, 202515-12G EDGAR
2. Dec 19, 2025SCHEDULE 13D/A EDGAR
3. Dec 19, 20254 OWNERSHIP DOCUMENT EDGAR
4. Dec 18, 2025EFFECT EDGAR
5. Dec 18, 2025EFFECT EDGAR
6. Dec 18, 2025EFFECT EDGAR
7. Dec 18, 2025EFFECT EDGAR
8. Dec 18, 2025EFFECT EDGAR
9. Dec 18, 2025EFFECT EDGAR
10. Dec 17, 2025S-8 POS EDGAR
11. Dec 17, 2025S-8 POS EDGAR
12. Dec 17, 2025S-8 POS EDGAR
13. Dec 17, 2025S-8 POS EDGAR
14. Dec 17, 2025S-8 POS EDGAR
15. Dec 17, 2025POS AM EDGAR
16. Dec 17, 2025POS AM EDGAR
17. Dec 17, 2025POS AM EDGAR
18. Dec 17, 2025POS AM EDGAR
19. Dec 17, 2025POS AM EDGAR
20. Dec 17, 2025POS AM EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Nantahala Capital Management, LLCSCHEDULE 13D/A, 6 filings Sep 20, 2024 to Dec 19, 2025⁴⁵
• Morgan StanleySCHEDULE 13G/A, 2 filings Sep 8, 2025 to Dec 5, 2025⁴⁶
• Roger M. KleinSCHEDULE 13D, 1 filing Nov 12, 2025⁴⁷
• Laurence W. LyttonSCHEDULE 13G/A, 3 filings Mar 13, 2024 to May 15, 2025⁴⁸
• Bleichroeder LPSCHEDULE 13G/A, 3 filings Mar 11, 2024 to Mar 24, 2025⁴⁹
• Altium Capital Management LLCSC 13G/A, 2 filings Feb 20, 2024 to Nov 14, 2024⁵⁰
• Orin HirschmanSC 13G/A, 2 filings Feb 13, 2024 to Oct 29, 2024⁵¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Evoke Pharma Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAREvoke Pharma Inc¹
• CIK0001403708
• Employer ID (EIN)20-8447886⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address420 Stevens Avenue, Suite 230, Solana Beach, CA 92075¹
• Phone858-345-1494¹
• Shares outstanding1,722,409 as of Nov 6, 2025¹²
• Public float$4.6M as of Jun 30, 2024⁴
• AuditorBDO USA, P.C., San Diego, California PCAOB ID 243; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceJun 11, 2007¹
• Filings665 in all: 8-K (196), 4 (194), 10-Q (37), 3 (28), CORRESP (19), SC 13G (17), DEFA14A (16), EFFECT (13)¹
  All 53 form types

  10-K (12), DEF 14A (12), 424B5 (11), SC 13G/A (10), S-1/A (9), UPLOAD (8), CT ORDER (6), POS AM (6), S-3 (5), S-8 (5), S-8 POS (5), PRE 14A (4), SCHEDULE 13G/A (4), SEC STAFF LETTER (4), 424B3 (3), ARS (3), SCHEDULE 13D/A (3), 424B4 (2), 5 (2), REGDEX/A (2), S-1 (2), SC 13D/A (2), SC TO-T/A (2), SC14D9C (2), 10-K/A (1), 144 (1), 15-12G (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), ARS/A (1), CERTNAS (1), D (1), DRS (1), FWP (1), POS EX (1), REGDEX (1), S-3/A (1), SC 13D (1), SC 14D9 (1), SC 14D9/A (1), SC TO-C (1), SC TO-T (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 13, 2025
  Quarterly report (10-Q) Nov 13, 2025
  Proxy statement (DEF 14A) Apr 10, 2025
  Latest 8-K (8-K) Dec 17, 2025

Securities registered for trading

From the cover page of the 10-K filed Mar 13, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Evoke Pharma Inc names in Item 1A of its 10-K filed Mar 13, 2025: 48 risks under these headings, as written.⁴

• Risks Related to our Business, including the Regulatory Compliance and Commercialization of our Product, Gimoti
• Our business is entirely dependent on the success of Gimoti, which may never generate sufficient sales to become profitable.
• We will require substantial additional funding and may be unable to raise capital when needed, which would force us to liquidate, dissolve or otherwise wind down our operations.
• We have no internal sales, marketing or distribution capabilities currently and rely on Eversana, and may rely on other third parties, for the commercialization of Gimoti, and we and they may not be able to effectively market, sell and distribute Gimoti.
• We and Eversana will need to retain qualified sales and marketing personnel and collaborate in order to successfully commercialize Gimoti.
• Use of Gimoti or any future product candidates we may develop could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of the approved labeling, or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.
• The results of the market research studies may not predict prescribing trends by doctors or acceptance by patients and are not intended to reflect or imply actual prescriptions or sales to date.
• Any termination or suspension of, or delays in the completion of, the post-marketing PK trial of Gimoti or any other future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
• Disruptions at FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
• Even though FDA has approved Gimoti for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis, we will remain subject to significant post-marketing regulatory requirements and oversight.
• FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
• It will be difficult for us to profitably sell Gimoti if coverage and reimbursement are limited.

Legal proceedings

We are not currently a party to any material legal proceedings. However, from time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.⁴